About Us
Since its founding, Metro International Biotech has built a world class, highly collaborative team of leading NAD+ experts, with extensive clinical and corporate experience, as well as in related fields such as metabolic pathways, drug development and manufacturing, molecular biology, isotopic labeling and nucleoside chemistry.
Our Mission
MetroBiotech is a clinical-stage biotechnology company developing first-in-class therapeutics that target NAD+ biology to enhance human healthspan and treat age-related diseases. Our mission is to address the root causes of aging-related conditions, improving the quality of life and treating the diseases of aging.
Our Foundation
Since our founding, we have built one of the most distinguished advisory boards in aging research, including pioneers in mitochondrial biology, NAD+ metabolism, and longevity science. Our chemistry-led approach – distinct from traditional biology-driven drug discovery – uniquely positions us to design highly precise, scalable, and pharmaceutical-grade NA modulators with broad therapeutic potential.
Our Programs
Our clinical programs, including MIB-626 and MIB-725, are advancing across indications such as acute kidney injury, muscle strength loss, diabetic kidney diseases, and neurocognitive disorders. We have demonstrated the ability to significantly elevate NAD+ levels in humans without any drug-related serious adverse events, positioning MetroBiotech to meet the growing demand for safe, effective treatments for age-related conditions.
Management Team
Edward SchulakChairman
David J. Livingston, MBA, Ph.D. President and Chief Scientific Officer
Bruce Szczepankiewicz, Ph.D. Vice President, Chemistry
David B. Pryor, M.D. Chief Medical Officer
Scientific Advisory Board
Rajendra Apte, M.D., Ph.D.
Johan Auwerx, M.D., Ph.D.
James Ellis, Ph.D.
Nick Lane, Ph.D.
Jeffrey Lieberman, M.D.
David Sinclair, A.O., Ph.D.
Li-Huei Tsai, Ph.D.
Lindsay Wu, Ph.D.
Siddhartha Mukherjee , M.D.
Jorge Alberto Costae Silva, M.D., ANM
Advancing Our Mission
